Literature DB >> 35611130

The Past, Present, and Future of Inflammatory Bowel Disease.

.   

Abstract

Entities:  

Year:  2021        PMID： 35611130      PMCID： PMC9122058     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  6 in total

1.  Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab.

Authors:  Bruce E Sands; Richard Kozarek; Jack Spainhour; Charles F Barish; Scott Becker; Lawrence Goldberg; Seymour Katz; Ronald Goldblum; Rena Harrigan; Deborah Hilton; Stephen B Hanauer
Journal:  Inflamm Bowel Dis       Date:  2007-01       Impact factor: 5.325

Review 2.  Novel Targeted Therapies for Inflammatory Bowel Disease.

Authors:  Mehmet Coskun; Severine Vermeire; Ole Haagen Nielsen
Journal:  Trends Pharmacol Sci       Date:  2016-12-01       Impact factor: 14.819

Review 3.  Immunomodulatory Agents for Treatment of Patients with Inflammatory Bowel Disease (Review safety of anti-TNF, Anti-Integrin, Anti IL-12/23, JAK Inhibition, Sphingosine 1-Phosphate Receptor Modulator, Azathioprine / 6-MP and Methotrexate).

Authors:  Lindsey Sattler; Stephen B Hanauer; Lisa Malter
Journal:  Curr Gastroenterol Rep       Date:  2021-12-16

Review 4.  Combining Biologics in Inflammatory Bowel Disease and Other Immune Mediated Inflammatory Disorders.

Authors:  Robert P Hirten; Marietta Iacucci; Shailja Shah; Subrata Ghosh; Jean-Frederic Colombel
Journal:  Clin Gastroenterol Hepatol       Date:  2018-03-02       Impact factor: 11.382

Review 5.  Efficacy, Safety and Future Perspectives of JAK Inhibitors in the IBD Treatment.

Authors:  Patrycja Dudek; Adam Fabisiak; Hubert Zatorski; Ewa Malecka-Wojciesko; Renata Talar-Wojnarowska
Journal:  J Clin Med       Date:  2021-11-30       Impact factor: 4.241

Review 6.  What is the future of targeted therapy in rheumatology: biologics or small molecules?

Authors:  Attila Mócsai; László Kovács; Péter Gergely
Journal:  BMC Med       Date:  2014-03-13       Impact factor: 8.775
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.